Abstracts developed to project lifetime costs and benefits of lipid therapy. Clinical trial data were used to estimate LDL-C reductions for different treatment strategies. Effect of LDL-C reductions on CHD event rates was estimated using Framingham equations and Spanish Instituto Nacional de Estadística data on nonCHDrelated mortality. Direct costs of CHD events in Spain, Spanish prices for simvastatin, atorvastatin and EZ10 were used to project lifetime costs. Model was run for a population consisting of all CHD and CHD-equivalent patients started on A10 in an observational Lipid Lowering Treatment study conducted in Spain, and not at LDL-C goal after 60 days of treatment. RESULTS: For these patients N = 54 (mean age 62.5 years, 64.8% male, lipid profile on A10 mean LDL-C 148.7 mg/dl, TC 225.9 mg/dl, HDL 45.9 mg/dl), switching to EZ10 coadministered with S20 compared to atorvastatin titration is projected to increase the life expectancy from 15.99 to 16.31 years for CHD patients and from 18.11 to 18.23 years for CHD equivalent patients with a discounted incremental cost per life year gained of 7,855 EURO for CHD patients and 15,356 for CHD equivalent patients. CONCLUSION: Switching to EZ10 coadministered with simvastatin for CHD and CHD equivalent patients not at goal on atorvastatin is projected to be a costeffective alternative to atorvastatin titration. OBJECTIVES: Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality. Treatment with statins has shown to be effective in controlling cholesterol levels in dyslipidemic subjects and in preventing CVD. The objective of this analysis was the evaluation of the economic impact of the CVD primary prevention with statins in Italy. METHODS: Alternatives: market mix for statins (low dosages assumed as initial dosages) marketed in Italy (weighted with the current market shares) compared with no intervention. Population: sample of high-risk subjects with an absolute CV risk level ≥ 2% per year, derived from a population study conducted in the Verona area in Italy. Perspective: National Health Service (NHS). Technique: cost-effectiveness analysis, making economic and health projections in a hypothetical cohort of 1000 subjects in primary prevention; an incremental cost per life year gained (ICER LYG) has been calculated. Time: 10 years. Costs: drugs and direct medical costs quantified in using NHS tariffs expressed in Euro 2003. Effects: the effects of different statins in controlling cholesterol levels, as measured with the CURVES study (Jones P et al, 1998) has been used to model coronary (CHD) morbidity and mortality from CVD with the Framingham risk equations (Anderson KM et al, 1990). RESULTS: A primary CVD preventive intervention with statins in a hypothetical cohort of 1000 high-risk subjects can avoid 70 CHD events and 28 CVD deaths, thus projecting 138 LYG. After having considered costs for drugs (4,789,542€) and savings due to events avoided (319,722€), the net cost of the intervention is 4,469,820€ with a ICER LYG of 32,458€. CONCLUSIONS: The cost-effectiveness profile of CVD primary preventive intervention with statins is in the range of what is considered cost-effective in absolute values by the scientific community.
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PCV36 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY
Bustacchini S 1 , Ruffo P 1 , Mantovani LG 2 1 Pfizer Italia srl, Rome, Italy; 2 University of Milan, Milan, Italy OBJECTIVES: Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality. Treatment with statins has shown to be effective in controlling cholesterol levels in dyslipidemic subjects and in preventing CVD. The objective of this analysis was the evaluation of the economic impact of the CVD primary prevention with statins in Italy. METHODS: Alternatives: market mix for statins (low dosages assumed as initial dosages) marketed in Italy (weighted with the current market shares) compared with no intervention. Population: sample of high-risk subjects with an absolute CV risk level ≥ 2% per year, derived from a population study conducted in the Verona area in Italy. Perspective: National Health Service (NHS). Technique: cost-effectiveness analysis, making economic and health projections in a hypothetical cohort of 1000 subjects in primary prevention; an incremental cost per life year gained (ICER LYG) has been calculated. Time: 10 years. Costs: drugs and direct medical costs quantified in using NHS tariffs expressed in Euro 2003. Effects: the effects of different statins in controlling cholesterol levels, as measured with the CURVES study (Jones P et al, 1998) has been used to model coronary (CHD) morbidity and mortality from CVD with the Framingham risk equations (Anderson KM et al, 1990) . RESULTS: A primary CVD preventive intervention with statins in a hypothetical cohort of 1000 high-risk subjects can avoid 70 CHD events and 28 CVD deaths, thus projecting 138 LYG. After having considered costs for drugs (4,789,542€) and savings due to events avoided (319,722€), the net cost of the intervention is 4,469,820€ with a ICER LYG of 32,458€. CONCLUSIONS: The cost-effectiveness profile of CVD primary preventive intervention with statins is in the range of what is considered cost-effective in absolute values by the scientific community.
PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY
Schädlich PK 1 , Lehmacher W 2 , Huppertz E 3 , Grewe R 3 , Brecht JG 1 1 InForMed GmbH-Outcomes Research and Health Economics, Ingolstadt, Bavaria, Germany; 2 Institute for Medical Statistics, Informatics, and Epidemiology of the University of Cologne, Cologne, NRW, Germany; 3 Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Hesse, Germany OBJECTIVES: To estimate-from the German SHI perspective-economic consequences of using the low-molecular-weight heparin enoxaparin subcutaneously (ENOX) instead of intravenous unfractionated heparin followed by oral phenprocoumon (UFH/PPC) for anticoagulation in patients undergoing TEEguided early electrocardioversion from nonvalvular atrial fibrillation (AF). METHODS: As ENOX is noninferior to UFH/PPC in preventing deaths and ischemic, embolic, and hemorrhagic events [Stellbrink C, et al. ACE trial. Circulation 2004] , a costminimization analysis (CMA) was performed. The target variable "incremental cost for ENOX versus UFH/PPC" was quantified using a modelling approach based on decision-tree technique. The CMA encompassed 28 (26-30) treatment days with phase I of 5 (3-8) days comprising diagnostics, initiation of anticoagulation, and cardioversion. Phase II with the remaining days comprised continued anticoagulation. Resource use was verified by a survey in the in-and outpatient sectors. Costs were given by SHI expenses and were quantified by multiplying utilised resource items by the price or tariff of each item, according to German Health Care regulations. RESULTS: In the basecase analysis, phase I was outpatient based for the majority of ENOX patients opposed to inpatient treatment for all UFH/PPC patients, whereas phase II was entirely outpatient based for both patient groups. There were savings of 579€ per patient with ENOX (892€) compared to UFH/PPC (1471€). Comprehensive sensitivity analyses (impact analysis, Monte Carlo simulation) showed the robustness of the model. Expenses for the inpatientbased phase I with UFH/PPC had by far the greatest influence on the extent of savings obtained. Simultaneous random variation of all model parameters within their empirically given intervals revealed savings obtained by ENOX in 93% of 10,000 simulated comparisons versus UFH/PPC. CONCLUSIONS: In TEE-guided early electrocardioversion of nonvalvular AF, anticoagulation with ENOX offers SHI in Germany an enormous saving potential when used instead of UFH/PPC.
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COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION
Avxentieva M,Vorobjov PA, Sura M Moscow Medical Academy, Moscow, Russia OBJECTIVE: To calculate costs for patients with myocardial infarction (MI) in common medical practice in Russian Federation. METHODS: Data on resource use for hospital treatment of patients with acute myocardial infarction were extracted from 99 medical charts at 3 hospitals at Moscow, Tula and Vladimir. Data on resource use for out-patient follow-up for patients after acute myocardial infarction were identified according to experts' opinion. A total of 12 experts filled in the questionnaire for identifying typical follow-up strategy for 1.5 years after MI. Direct medical costs were calculated on the basis of price-lists for medical services and median prices for drugs given in a wholesale pharmaceutical informational bulletin. RESULTS: Median
